Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma

Immunocore announced Phase 1/2 trial results showing a combination of brenetafusp and KIMMTRAK achieved a 70% two-year overall survival rate in 17 first-line metastatic uveal melanoma patients, with a 29% overall response rate and manageable safety profile. The company plans to initiate a Phase 2/3 randomized trial (DUET-UVEAL) to further evaluate the combination therapy.